On the basis of the genetic findings and the mouse studies, in 2014 we initiated a clinical trial of tocilizumab in participants with mild asthma, specifically those with CT or TT genotype for rs4129267, as these have markedly increased levels of sIL-6R levels.94 Results from this trial are expected to be published in 2018. Here, IL6R is linked to asthma.